Personalized vs standard therapy for relapsed small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial compares two treatment approaches for people with relapsed extensive-stage small cell lung cancer. One approach uses a lab-grown tumor model (called an organoid) to pick a personalized drug, while the other uses a standard chemotherapy called topotecan.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have extensive-stage small cell lung cancer (the cancer has spread beyond one lung).
- You received one line of platinum-based chemotherapy and the cancer came back or progressed within 6 months of finishing it.
- You have a tumor sample or pleural fluid that can be collected for lab testing (to grow 'organoids' – mini tumors).
- You have measurable tumors on imaging scans.
- You are physically active (ECOG 0 or 1 – able to do daily activities).
- Your blood, kidney, and liver functions are adequate.
- Brain metastases are allowed only if they are stable and not causing symptoms.
- You agree to use effective contraception if applicable, and not to donate sperm or eggs during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a second course of chemotherapy and an immunotherapy drug (atezolizumab) for people with extensive-stage small cell lung cancer that has returned after initial treatment. The goal is to see if re-using these treatments together can help control the cancer again.
This trial tests a new combination of two drugs for people with extensive-stage small cell lung cancer that has progressed after initial treatment. The goal is to see if this combination can help control the cancer.
This trial tests a chemotherapy drug called nab-paclitaxel combined with other local treatments (like radiation) for people with small cell lung cancer that has returned after initial treatment. The goal is to see if this combination helps control the cancer and improves outcomes.
This trial tests immunotherapy drugs for extensive stage small cell lung cancer that has progressed after initial (first-line) chemotherapy. You may be eligible if you have finished standard treatment and your cancer has worsened.
This trial tests different experimental drugs matched to the specific genetic makeup of your small cell lung cancer. The goal is to see if targeting your cancer's particular molecular type can shrink tumors or delay their growth better than standard care.
This trial tests a new drug called MHB088C for people with small cell lung cancer that has come back or gotten worse after standard treatments. It compares this drug to other options your doctor might choose. The goal is to see if MHB088C works better.
Hear when a new Extensive-stage Small Cell Lung Cancer (ES-SCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.